eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | leishmaniasis |
| Comorbidity | C0030305|pancreatitis |
| Sentences | 2 |
| PubMedID- 22469394 | Use of meglumine antimonate (glucantime; sanofi, paris, france), a drug of choice for the treatment of leishmaniasis, was contraindicated because of pancreatitis in the patient and in vitro isolate susceptibility variation; therefore, induction therapy consisted of liposomal amphotericin b (ampb [ambisome; astellas pharma us, deerfield, il, usa]) at a dose of 3 mg/kg/d for 5 consecutive days, then 1× week for 5 weeks (total dose 30 mg/kg) during 1998–2000 (table). |
| PubMedID- 24346389 | Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment. |
Page: 1